Late-breaker host Dr Harriette Van Spall (McMaster University, CA) invites PI, Dr John Spertus to discuss the innovative CHIEF-HF clinical trial.
The aim of this study was to determine the superiority of the effectiveness of canagliflozin versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS).
Presented first at AHA 2021, the trial showed that canagliflozin improved symptoms and quality of life within three months for individuals with heart failure.
Recorded remotely from Kansas City and Hamilton, 2021.
Editor: Mirjam Boros